Cabergoline is the first-line treatment for PRL-secreting PitNETs, and in female patients who are often able to start treatment at an early stage, it is effective within a short period after initiation, with PRL normalization and tumor shrinkage rates of >90%. The gene discussed is PRL; the disease is neoplasm.